Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2012


#152993

494pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. 

It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
  • A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer 15
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics under Development by Companies 17
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Comparative Analysis 31
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Products under Development by Companies 32
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Products under Investigation by Universities/Institutes 38
Companies Involved in Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Development 43
Bristol-Myers Squibb Company 43
Johnson & Johnson 44
Boehringer Ingelheim GmbH 45
Abbott Laboratories 46
Amgen Inc. 47
Sanofi-Aventis 48
Eli Lilly and Company 49
Genentech, Inc. 50
Isis Pharmaceuticals, Inc. 51
Merck & Co., Inc. 52
Emergent BioSolutions Inc. 53
Plexxikon Inc. 54
BioSante Pharmaceuticals, Inc. 55
Millennium Pharmaceuticals, Inc. 56
Novartis AG 57
Aphios Corporation 58
Astellas Pharma Inc. 59
BioMarin Pharmaceutical Inc. 60
Agennix AG 105
CytoVac A/S 106
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Assessment 107
Assessment by Monotherapy Products 107
Assessment by Combination Products 108
Assessment by Route of Administration 109
Assessment by Molecule Type 111
Drug Profiles 114
zoptarelin doxorubicin - Drug Profile 114
ipilimumab - Drug Profile 116
pasireotide - Drug Profile 118
sabarubicin - Drug Profile 120
DI-17-E-6 - Drug Profile 122
orteronel - Drug Profile 124
cixutumumab - Drug Profile 126
RG-7422 - Drug Profile 127
PSMA ADC - Drug Profile 129
GTx-758 - Drug Profile 131
ISIS-EIF4ERx - Drug Profile 132
OGX-427 - Drug Profile 133
CDX-1127 - Drug Profile 135
ridaforolimus - Drug Profile 136
ASG-5-ME - Drug Profile 139
MT-110 - Drug Profile 141
enzalutamide - Drug Profile 143
ADX-68692 - Drug Profile 145
AT-13387 - Drug Profile 146
HE-3235 - Drug Profile 148
AMPI-109 - Drug Profile 150
Cyp17 Inhibitor Program - Drug Profile 151
cabozantinib - Drug Profile 152
galeterone - Drug Profile 154
docetaxel - Drug Profile 155
TheraCIM + Mitoxantrone + Prednisone - Drug Profile 157
mepacrine - Drug Profile 159
PX-866 - Drug Profile 162
radium Ra 223 dichloride - Drug Profile 163
bavituximab - Drug Profile 165
APC-300 - Drug Profile 167
TSD-0014 - Drug Profile 168
AUS-131 - Drug Profile 170
Anti-PSMA Designer T Cells - Drug Profile 172
dovitinib lactate - Drug Profile 173
ETS-2123 - Drug Profile 175
cediranib maleate - Drug Profile 307
Temsirolimus + Docetaxel - Drug Profile 308
paclitaxel protein-bound particles for injectable suspension - Drug Profile 309
inecalcitol - Drug Profile 310
JW-1521 - Drug Profile 312
Rapamycin + PD0325901 - Drug Profile 313
aflibercept - Drug Profile 314
Docetaxel + Prednisone - Drug Profile 316
sorafenib tosylate - Drug Profile 317
STA-9090 - Drug Profile 318
EZN-4176 - Drug Profile 319
APH-0701 - Drug Profile 321
Lm Prostate - Drug Profile 322
LY2181308 + Docetaxel - Drug Profile 323
EZN-4176 + MDV-3100 - Drug Profile 325
LFA-102 - Drug Profile 326
KX-01 - Drug Profile 328
ODM-201 - Drug Profile 330
Oxaliplatin + Pemetrexed Disodium - Drug Profile 331
Bavituximab + Cabazitaxel - Drug Profile 332
Revlimid + Avastin + Docetaxel + Prednisone - Drug Profile 333
Docetaxel + Estramustine - Drug Profile 335
RAD001 + Bevacizumab + Docetaxel - Drug Profile 336
Abiraterone Acetate + Prednisone + Docetaxel - Drug Profile 337
CB-7630 + Prednisone - Drug Profile 339
IRX-4204 - Drug Profile 341
SARD Program - Drug Profile 343
MG-1102 - Drug Profile 344
Docetaxel + Pasireotide + Prednisone - Drug Profile 345
GDC-0068 + Abiraterone + Prednisone - Drug Profile 347
GDC-0980 + Abiraterone + Prednisone - Drug Profile 349
Luprolide + Docetaxel + Prednisolone - Drug Profile 351
VT-464 - Drug Profile 353
Cabazitaxel + Carboplatin + Prednisone - Drug Profile 354
Cabazitaxel + Abiraterone + Prednisone - Drug Profile 356
TeloB-VAX - Drug Profile 358
OGX-427 + Zytiga - Drug Profile 360
Cabozantinib + Abiraterone + Prednisone - Drug Profile 361
degarelix acetate - Drug Profile 362
Sodium Selenate - Drug Profile 363
Anti-PSMA X Anti-CD3 - Drug Profile 365
Carboplatin + Paclitaxel - Drug Profile 366
Cabozantinib + Abiraterone - Drug Profile 367
Arkil - Drug Profile 368
Cabazitaxel + Mitoxantrone + Prednisone - Drug Profile 370
naltrexone - Drug Profile 371
CFG-920 - Drug Profile 372
PEGrHuPH20 + Docetaxel - Drug Profile 373
PEGrHuPH20 + Liposomal Doxorubicin - Drug Profile 374
Metformin + Abiraterone - Drug Profile 375
AT-13387 + Abiraterone Acetate - Drug Profile 376
colchicine - Drug Profile 377
Dendritic Cell Vaccination + Docetaxel - Drug Profile 378
DSTP-3086S - Drug Profile 379
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Drug Profile Updates 380
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Discontinued Products 455
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Dormant Products 459
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Product Development Milestones 470
Featured News & Press Releases 470

Appendix 481
Methodology 481
Coverage 481
Secondary Research 481
Primary Research 481
Expert Panel Validation 481
Contact Us 482
Disclaimer 482

Number of Products Under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2012 27
Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Comparative Analysis, H2 2012 28
Number of Products under Development by Companies, H2 2012 30
Number of Products under Development by Companies, H2 2012 (Contd..1) 31
Number of Products under Development by Companies, H2 2012 (Contd..2) 32
Number of Products under Development by Companies, H2 2012 (Contd..3) 33
Number of Products under Development by Companies, H2 2012 (Contd..4) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 39
Comparative Analysis by Late Stage Development, H2 2012 40
Comparative Analysis by Mid Clinical Stage Development, H2 2012 41
Comparative Analysis by Early Clinical Stage Development, H2 2012 42
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 43
Products under Development by Companies, H2 2012 44
Products under Development by Companies, H2 2012 (Contd..1) 45
Products under Development by Companies, H2 2012 (Contd..2) 46
Products under Development by Companies, H2 2012 (Contd..3) 47
Products under Development by Companies, H2 2012 (Contd..4) 48
Products under Development by Companies, H2 2012 (Contd..5) 49
Products under Investigation by Universities/Institutes, H2 2012 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 54
Bristol-Myers Squibb Company, H2 2012 55
Johnson & Johnson, H2 2012 56
Boehringer Ingelheim GmbH, H2 2012 57
Abbott Laboratories, H2 2012 58
Amgen Inc., H2 2012 59
Sanofi-Aventis, H2 2012 60
Eli Lilly and Company, H2 2012 61
Genentech, Inc., H2 2012 62
Isis Pharmaceuticals, Inc., H2 2012 63
Merck & Co., Inc., H2 2012 64
Emergent BioSolutions Inc., H2 2012 65
Plexxikon Inc., H2 2012 66
BioSante Pharmaceuticals, Inc., H2 2012 67
Millennium Pharmaceuticals, Inc., H2 2012 68
Novartis AG, H2 2012 69
Aphios Corporation, H2 2012 70
Astellas Pharma Inc., H2 2012 71
BioMarin Pharmaceutical Inc., H2 2012 72
GTx, Inc., H2 2012 73
Orion Corporation, H2 2012 74
SuperGen, Inc., H2 2012 75
Teva Pharmaceutical Industries Limited, H2 2012 76
Progenics Pharmaceuticals, Inc., H2 2012 77
Santaris Pharma A/S, H2 2012 78
Exelixis, Inc., H2 2012 79
Aduro BioTech, H2 2012 80
Menarini Group, H2 2012 81
Celgene Corporation, H2 2012 82
Bayer AG, H2 2012 83
Halozyme Therapeutics, H2 2012 84
Merck KGaA, H2 2012 85
Addex Pharmaceuticals, H2 2012 86
Hollis-Eden Pharmaceuticals, Inc., H2 2012 87
Celldex Therapeutics, Inc., H2 2012 88
ValiRx Plc, H2 2012 89
AEterna Zentaris Inc., H2 2012 90
Cleveland BioLabs, Inc., H2 2012 91
Oncolytics Biotech Inc., H2 2012 92
Oncothyreon Inc, H2 2012 93
Peregrine Pharmaceuticals, Inc., H2 2012 94
Medivation, Inc., H2 2012 95
Poniard Pharmaceuticals, Inc., H2 2012 96
Regeneron Pharmaceuticals, Inc., H2 2012 97
Oncogenex Pharmaceuticals, Inc., H2 2012 98
Green Cross Corporation, H2 2012 99
Threshold Pharmaceuticals, Inc., H2 2012 100
e-Therapeutics plc, H2 2012 101
Hybrigenics S.A., H2 2012 102
Nerviano Medical Sciences S.r.l., H2 2012 103
CureVac GmbH, H2 2012 104
GenSpera, Inc., H2 2012 105
Ascenta Therapeutics, Inc., H2 2012 106
Tokai Pharmaceuticals, Inc., H2 2012 107
TSD Japan, Inc., H2 2012 108
Kinex Pharmaceuticals, LLC, H2 2012 109
Adamis Pharmaceuticals Corporation, H2 2012 110
TRACON Pharmaceuticals, Inc., H2 2012 111
Viamet Pharmaceuticals, Inc., H2 2012 112
Aragon Pharmaceuticals, Inc., H2 2012 113
Vakzine Projekt Management GmbH, H2 2012 114
Ausio Pharmaceuticals, LLC, H2 2012 115
Errant Gene Therapeutics, LLC, H2 2012 116
Agennix AG, H2 2012 117
CytoVac A/S, H2 2012 118
Assessment by Monotherapy Products, H2 2012 119
Assessment by Combination Products, H2 2012 120
Assessment by Stage and Route of Administration, H2 2012 122
Assessment by Stage and Molecule Type, H2 2012 125
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Drug Profile Updates 392
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Discontinued Products 467
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Discontinued Products (Contd..1) 468
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Discontinued Products (Contd..2) 469
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Discontinued Products (Contd..3) 470
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products 471
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..1) 472
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..2) 473
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..3) 474
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..4) 475
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..5) 476
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..6) 477
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..7) 478
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..8) 479
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..9) 480
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..10) 481
Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2012 27
Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Comparative Analysis, H2 2012 28
Products under Development by Companies, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 35
Late Stage Products, H2 2012 40
Mid Clinical Stage Products, H2 2012 41
Early Clinical Stage Products, H2 2012 42
Discovery and Pre-Clinical Stage Products, H2 2012 43
Assessment by Monotherapy Products, H2 2012 119
Assessment by Combination Products, H2 2012 120
Assessment by Route of Administration, H2 2012 121
Assessment by Stage and Route of Administration, H2 2012 122
Assessment by Molecule Type, H2 2012 123
Assessment by Stage and Molecule Type, H2 2012 124